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Lenalidomide Therapy in Treatment Refractory Cutaneous Lupus
Erythematosus: Histologic and Circulating Leukocyte Profile and
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Abstract
Background
Lenalidomide is a thalidomide analogue that may serve as an adjunctive therapy for treatment refractory
cutaneous lupus erythematosus (CLE).
Objectives
We evaluate the use of lenalidomide in CLE and describe the skin and circulating leukocyte profile of
treatment refractory patients before and after treatment.
Patients/Methods
Five subjects were treated with lenalidomide in an unblinded open-label study. Immunohistochemistry of skin
was performed for T-cell markers, glycosaminoglycans and CXCL10, an interferon (IFN)-inducible
chemokine, before and after treatment. Immunophenotyping and measurement of IFN-inducible genes from
peripheral blood mononuclear cells was also performed before and after treatment.
Results
Four subjects demonstrated clinical improvement of their skin, however one of these responders subsequently
developed symptoms of systemic lupus erythematosus. Small changes in rare circulating leukocyte subsets,
plasmacytoid dendritic cells and regulatory T-cells, were observed with treatment and may correlate with
clinical response. Treatment was associated with increased circulating HLA-DR expression and decreased
markers of IFN-mediated pathways, regardless of clinical response.
Limitations
Our results are limited by small sample size and the measurement of rare populations of circulating cell
subsets.
Conclusions
Lenalidomide may have utility as therapy for severe, treatment refractory CLE. However, our preliminary data
suggest that lenalidomide may activate T-cells and trigger systemic disease in some CLE patients. We also saw
a unique histologic and circulating leukocyte phenotype in the nonresponding subject. Further
characterization of the skin and circulating leukocyte profile of treatment refractory patients will improve our
understanding of CLE.
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Abstract
Background—Lenalidomide is a thalidomide analogue that may serve as an adjunctive therapy
for treatment refractory cutaneous lupus erythematosus (CLE).
Objectives—We evaluate the use of lenalidomide in CLE and describe the skin and circulating
leukocyte profile of treatment refractory patients before and after treatment.
Patients/Methods—Five subjects were treated with lenalidomide in an unblinded open-label
study. Immunohistochemistry of skin was performed for T-cell markers, glycosaminoglycans and
CXCL10, an interferon (IFN)-inducible chemokine, before and after treatment.
Immunophenotyping and measurement of IFN-inducible genes from peripheral blood
mononuclear cells was also performed before and after treatment.
Results—Four subjects demonstrated clinical improvement of their skin, however one of these
responders subsequently developed symptoms of systemic lupus erythematosus. Small changes in
rare circulating leukocyte subsets, plasmacytoid dendritic cells and regulatory T-cells, were
observed with treatment and may correlate with clinical response. Treatment was associated with
increased circulating HLA-DR expression and decreased markers of IFN-mediated pathways,
regardless of clinical response.
Limitations—Our results are limited by small sample size and the measurement of rare
populations of circulating cell subsets.
Conclusions—Lenalidomide may have utility as therapy for severe, treatment refractory CLE.
However, our preliminary data suggest that lenalidomide may activate T-cells and trigger systemic
disease in some CLE patients. We also saw a unique histologic and circulating leukocyte
phenotype in the nonresponding subject. Further characterization of the skin and circulating
leukocyte profile of treatment refractory patients will improve our understanding of CLE.
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Introduction
Approximately 10% of patients with cutaneous lupus erythematosus (CLE) are refractory to
established therapies, including thalidomide1. CLE has been reported to have the same
incidence as systemic lupus erythematosus (SLE), approximately 3 per 100,000,
highlighting the need for improved therapies2. Lenalidomide, a thalidomide analogue with
more potent T-cell, IL-2 and Interferon (IFN)-γ stimulating effects in vitro compared to
thalidomide, is a potential alternative or adjunctive treatment for severe generalized discoid
lupus erythematosus (DLE)3. It is an immunomodulatory drug shown to stimulate T-cells,
natural killer (NK)-cells and anti-inflammatory cytokines and inhibit tumor necrosis factor
alpha (TNF-α) production and angiogenesis4.
The current CLE pathogenesis model implicates IFN-inducible proteins and chemokines in
the recruitment and activation of inflammatory cells in the skin5-8. Plasmacytoid dendritic
cells (pDCs) accumulate in CLE skin and produce type I IFNs which may initiate the
inflammatory cascade8-11. IFN-inducible chemokines, like CXCL9, CXCL10 and CXCL11,
are highly expressed around lymphocytes in CLE lesions, supporting a potential role in cell
recruitment5, 7, 8. The lymphocytic infiltrate also expresses cutaneous lymphocyte antigen
(CLA), a skin-homing receptor 12. CLE lesions have increased glycosaminoglycans (GAG)
content and are characterized by low numbers of regulatory T-cells (Tregs).13
There is evidence of B- and T-cell activation in the peripheral blood of patients with DLE
and subacute cutaneous lupus erythematosus (SCLE)14-17. In DLE absolute circulating
lymphocyte numbers are similar to healthy controls, but SCLE patients have decreased
absolute circulating CD4+ and CD8+ T-cells18-20. No difference in circulating Treg counts
have been seen in DLE, SCLE or tumid lupus erythematosus (TLE)13. Investigators have
observed severe scarring DLE to have increased expression of circulating CCR4+ and CLA
+ cells (skin-homing receptors) and decreased CXCR3+ expression, a chemokine receptor
associated with IFN-signaling6, 21.
These circulating changes support the growing evidence of systemic alterations in the
inflammatory cascade in CLE. Recently we found elevated IFN-inducible genes in blood
from patients with DLE and SCLE22. A polymorphism in Interferon regulatory factor 5
(IRF5) in DLE and SCLE has been described23. Additionally, mutations in TREX1, a DNA
exonuclease implicated in SLE and Aicardi-Goutieres syndrome, have been reported in a
familial form of chilblain lupus, suggesting a shared pathogenesis between these conditions
manifesting with elevated serum IFN-α24, 25.
Here we investigate the use of lenalidomide in five patients with CLE. We examined
histology, circulating leukocyte subsets and markers of IFN-mediated signaling, in the skin
and blood, before and after treatment to better characterize the pathophysiology of this
refractory patient subset and gain insight into the mechanism of action of lenalidomide. We
also describe one patient who developed SLE during lenalidomide therapy.
Materials and methods
Patients
Five patients were enrolled according to the following inclusion criteria: 1) DLE or SCLE
diagnosis, 2) no response to 3 months of hydroxychloroquine and 3) participation in
RevAssist®, a distribution program run by the manufacturers of lenalidomide26. Patients
with SLE (by ACR criteria), who were pregnant, had thrombocytopenia, lymphopenia,
neutropenia or a history of deep venous thrombosis or pulmonary embolism were excluded.
Informed consent was obtained. Subjects received 5 mg oral lenalidomide daily during the
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first six weeks of treatment. Patients were maintained on all baseline medications. The study
protocol was approved by the University of Pennsylvania Institutional Review Board.
Skin biopsy collection
A punch biopsy of lesional skin was taken at weeks 0, 2, and 6 of treatment. A biopsy of
non-lesional skin was taken at week 0. Half of each biopsy was fixed in formalin and the
other half frozen in liquid nitrogen. Week 2 biopsies were refused by subjects 4 and 5.
Assessment of clinical disease activity
Disease activity was assessed using the CLASI (cutaneous lupus area and severity index)
activity score27, 28. A partial response reflects a four-point decrease in CLASI activity score
(Klein et al. in press). VPW or MR performed all CLASI scoring.
Immunohistochemical staining
Immunohistochemical (IHC) staining was performed on formalin-fixed, paraffin-embedded
skin biopsy samples using: monoclonal mouse anti-CD3 (Novacastra, Clone PS1, Newcastle
upon Tyne, UK), anti-CD4 (Novacastra, Clone IF6), anti-CD8 (Dako, Clone C8/144B,
Glostrup, Denmark), rat anti-CLA (BD Pharmingen, Clone HECA-452, San Jose,
California), and polyclonal goat anti-CXCL10/IP-10, (interferon-γ inducible protein ten)
(R&D Systems, Minneapolis, MN). Isotype control reactions were performed with mouse
IgG1 (Sigma, Clone MOPC 21, St. Louis, MO) for CD4 and CD8, mouse IgG2a (Dako,
Clone DAK-G05) for CD3, goat total IgG (R&D systems) for CXCL10, and rat IgM, K
isotype (BD Pharmigen, Clone R4-22) for CLA. Indirect IHC staining was performed with
Dako LSAB™ system, except for CLA where biotinylated mouse anti-rat IgM (IgG1) (BD
Pharmigen, Clone G53-238) was the secondary antibody. Staining was visualized using
NovoRed chromogen (Vector Labs, Burlingame, CA) or DAB chromogen (Dako).
Hematoxylin and Eosin (H&E) and Hale’s stain were performed using established
protocols29.
Immunohistochemical staining quantification
CXCL10 staining was quantified using ImagePro (MediaCybernetics, Bethesda, MD).
Percent staining was calculated from six high-power-field (HPF) images (400x). CD3, CD4,
CD8, and CLA staining was quantified using the cell counter plugin on ImageJ Software
(NIH, Bethesda, MD).
Peripheral blood collection and flow cytometry
Peripheral blood cells were obtained at weeks 0, 2, and 6 of treatment. A complete blood
count with differential and immunofluorescence was performed. Monoclonal antibodies
were added directly to 150 μl aliquots of whole blood and incubated at room temperature for
20 minutes. Red blood cells were lysed with ammonium chloride lysing buffer (BD Pharm
Lyse). Remaining mononuclear cells were washed using wash buffer (Dulbecco’s PBS with
5% fetal calf serum and sodium azide). Cells were fixed in 1% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA).
The following antibodies were used: FITC-HLA-DR (clone L243), FITC-CLA (clone
HECA-452), PE-CD123 (clone 9F5), PE-CD127 (clone hIL-7R-M21), PerCP-CD4 (clone
SK3), APC-HLA-DR (clone L243), APC-CD25 (clone M-A251), APC-CD27 (clone L128),
PE-Cy5-CD40 (clone 5C3), and PE-Cy7-CD19 (clone SJ25C1) (all BD Pharmigen). APC-
Cy5.5 -CD38 (clone HIT2), APC-Alexa Fluor 750-CD3 (clone S4), PE-TR-CD4 (clone
S3.5), and PE-Cy5.5-CD5 (clone 5D7) (all Caltag/Invitrogen, Carlsbad, CA). Alexa Fluor
700 -CD33 (clone WM-53) and PE-Cy7-CD11c (clone 2.9) (eBioscience, San Diego, CA).
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Dead cell exclusion was performed using the Live/Dead Fixable Violet Dead Cell Stain Kit
(Invitrogen, Carlsbad, CA). The sample preparation, instrument operation and data analysis
was performed by the same operator to control for inter-operator variability. Flow cytometry
was performed on the same instrument (Becton Dickinson LSR2 Benchtop Flow Cytometer)
to control for machine variability. Data was analyzed using v.8.2 Flow Jo software (Treestar
Inc, Eugene, OR).
Type I IFN-inducible gene expression
Five IFN-inducible genes were studied: lymphocyte antigen 6 complex, locus E (LYGE),
Hs00158942_m1; 2’,5’-oligoadenylate synthetase 1, 40/46 kd (OAS1), HS00242943_m1;
2’,5’-oligoadenylate synthetase-like (OASL), Hs00388714_m1; myxovirus resistance 1
(MX1), Hs00182073_m1 and interferon-α-inducible protein (clone IFI-15K) (ISG15),
Hs00192713_m1 (Applied Biosystems, Foster City, CA). Total RNA was extracted from
peripheral blood using RNA Later, Qiagen RNeasy Minikit and Qiashredder Minicolumns
(Qiagen, Valencia, CA). Total RNA was reverse transcribed into complementary DNA
(Invitrogen First-Strand cDNA Synthesis Kit). RNA was stored at -70°C and cDNA samples
stored at -20°C. Gene expression was measured by real time PCR using ABI Prism 7000
sequence detection system and normalized to GAPDH (Taqman assay: Hs99999905_m1)
using ABI Prism SDS 7000 software, version 1.0 (Applied Biosystems). Experiments were
performed in triplicate in 25 μl of TaqMan Universal PCR Master Mix (Applied
Biosystems). Samples were denatured for 2 minutes at 50°C then 10 minutes at 95°C,
followed by 40 cycles at 95°C for 15 seconds and combined primer annealing and extension
at 60°C for 1 minute. IFN scores were calculated using published methods30.
Statistical analysis
A Wilcoxon signed rank test was performed to evaluate changes in IFN score and IHC
staining with treatment.
Results
We present the clinical response to lenalidomide in five subjects and describe the histologic
features and circulating leukocyte profile before and after treatment. Expression levels of
IFN-inducible genes in blood before and after treatment are shown as a measure of systemic
IFN-mediated signaling.
Clinical Response
Age, sex, race/ethnicity, diagnosis and medications are listed for each subject (Table 1).
Four subjects demonstrated satisfactory clinical improvement in their skin. The CLASI
activity scores at weeks 0, 2 and 6 are shown for each patient. All subjects demonstrated at
least a four-point drop from week 0 to 6, consistent with a partial response; however, four
subjects had more pronounced changes, with a drop in CLASI activity score of at least 8
points and will be referred to as responders. Subject 2, a female with generalized DLE, had a
five-point decrease in her CLASI score, however this was felt to be clinically unsatisfactory
and she was withdrawn from the study at week 12. She will be referred to as the
nonresponder. Among the responders were three females with DLE (subjects 1, 4 and 5) and
one male with a mixed clinical phenotype of SCLE and TLE (subjects 3). Although subject
5 experienced improvement in her skin lesions, she developed new-onset proteinuria and an
exacerbation of arthralgias at week 20 prompting withdrawal from the study.
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Histologic features of severe treatment refractory CLE
Week 0 lesional biopsies showed features of CLE. H&E, CD3, CD4, CD8 and CLA IHC
staining from a representative subject, subject 4,at week 0 are shown (Figure 1). Complete
absolute counts for cell marker and CD4:CD8 and CLA:CD3 ratios are shown (Table 2).
The inflammatory infiltrate was composed of predominantly CD3+ lymphocytes, in
accordance with previous findings8-10. The CD3+ infiltrate had 15 - 66% CLA expression
(mean ± SEM: 36 ± 8%). Three responders had CD8 predominance and two subjects had
CD4 predominance, including the nonresponder and subject 1. GAG levels were high in all
subjects at week 0. Representative images from two subjects are shown(Figure 2A and 2B).
CXCL10 expression was seen in lesional biopsies only and was most prominent in basal
keratinocytes and around the inflammatory infiltrate. Representative images of week 0
CXCL10 staining in two subjects are shown (Figure 3A and 3E). There were areas of
cytoplasmic speckling in basal keratinocytes and lymphocytes(Figure 3B and 3F).
Histologic findings after treatment with lenalidomide
A decrease in absolute numbers of CD3, CD4, CD8 and CLA cells was seen in from week 0
to 6, however the decrease did not reach statistical significance (Table 2). GAGs decreased
with treatment in three responding subjects, all with DLE. Representative images are shown
from subject 4 and the nonresponder who did not show a decrease in GAGs (Figure 2).
Decreased CXCL10 staining from week 0 to 6 was seen in all subjects, regardless of clinical
response. Representative images from the nonresponder, and subject 3 are shown (Figures
3A-3H). Quantification of CXCL10 staining is graphed (Figure 3I). The nonresponder had
markedly more CXCL10 staining than responders at week 0 followed by a peak at week 2
and subsequent decrease below week 0 levels at week 6.
Decreased IFN-inducible gene expression (IFN score), irrespective of clinical response
In three subjects with available data the IFN score decreased from week 0 to 2. Pre-
lenalidomide scores (week 0) were 29.5 ± 1.4 (mean ± SEM) and post-lenalidomide scores
(week 2) were 7.3 ± 2.4 (p=ns). In separate experiments we found a correlation between IFN
score and CLASI activity score22. However in the setting of treatment with lenalidomide in
this subject pool there was no correlation.
Changes in circulating lymphocyte subsets may correlate with clinical response
We examined the circulating leukocyte profile of the treatment refractory subjects and show
baseline values in Table 3. The nonresponder had granulocytopenia and the highest levels of
circulating CD4+ and CD8+ memory T-cells (CD45Ra-), CD19+ B-cells and activated
CD4+ T-cells (HLA-DR+) at baseline. There was no clear change in circulating CD3+,
CD4+, CD8+ or CLA+ T-cell percentages between week 0 and 6. Changes in rare cell
subsets implicated in the pathogenesis of CLE appeared to trend with clinical response.
Responders had a relative decrease in circulating pDCs compared to the nonresponder
(Figure 4A). We also saw an increase in absolute frequencies of circulating Tregs in three
responders (Figure 4B). Absolute frequencies of activated CD4+ T-cells increased in four
subjects, including the nonresponder (Figure 4c).
Subject 5 had unique findings of interest in light of her systemic disease flare, including
lymphopenia (800 cells/μl) at weeks 2 and 6, and an increase in activated pDCs from week 0
to 6 (Figure 4D).
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Discussion
Four of five patients with treatment refractory CLE had a clinically satisfactory response to
lenalidomide. Two of the responders (subjects 1 and 3) and the nonresponder previously
failed thalidomide therapy. Lesional biopsies showed histologic features of CLE including
CD3+ infiltrate and GAG accumulation. Two subjects had a CD4 predominant infiltrate, in
keeping with prior reports9, 10. Recent investigation suggests CD4 predominance better
characterizes SCLE and TLE, while CD8 predominance characterizes scarring subsets like
DLE and lupus profundus7, 21, 31, 32. Two subjects with CD8 predominance had a scarring
DLE phenotype and the other had SCLE/TLE overlap. CLA staining of the infiltrate was
variable in accordance with previous findings, suggesting a range of CLA+ expression in
CLE lesions12.
We saw decreased GAG content in three responding subjects with DLE. We find this
interesting given the immunologic activity of GAGs, specifically their ability to stimulate
dendritic cells via toll-like receptors33, 34. Further study into the role of these molecules in
the pathogenesis of CLE is warranted.
To assess the predominant model of IFN-mediated signaling in CLE pathogenesis, we
analyzed CXCL10 expression in the skin and the IFN-inducible gene expression in the
peripheral blood before and after treatment. CXCL10 gene expression increases in
keratinocytes after stimulation with IFN-α; however, the same response has been seen in
apoptotic keratinocytes treated with IFN-γ5, 6, 35. This suggests CXCL10 may also reflect
type II IFN-mediated signaling, however, CXCL10 is expressed at significantly higher
levels in CLE lesions than in other inflammatory dermatoses, suggesting specificity for CLE
pathogenesis5.
All lesional biopsies had significant CXCL10 staining. The nonresponder had the highest
levels, peaking to involve greater than 15% of the section at week 2 (Figure 3). However, all
subjects had lower CXCL10 staining at week 6 than baseline. Also, the IFN score of three
subjects decreased with treatment irrespective of the clinical response.
A small body of literature characterizing the circulating leukocyte phenotype in CLE exists.
We add characteristics of severe treatment refractory CLE (Table 3). Prior studies showed
increased circulating CLA+ CD4+ and CD8+ T-cells in generalized DLE compared to
healthy controls21. Here we observed less circulating CLA+ leukocytes than described using
the same antibody clone. Also we noted the nonresponder to have unique baseline findings
including granulocytopenia, and higher levels of B cells, and memory and activated T cells.
Further study is needed to determine if these findings have prognostic value.
No significant changes in the circulating leukocyte profile was seen with treatment, however
rare circulating subsets appeared to trend with clinical response. Responders had a decrease
in circulating pDCs and an increase in circulating Tregs from week 0 to 6 (Figure 4A and
4B). Although these represent rare subsets and the changes represent small changes in
absolute number, both cell types have been implicated in the pathophysiology of CLE. The
decrease in pDCs in responders is interesting given their ability to produce type I IFNs. Prior
studies showed normal numbers of circulating Tregs in CLE. Here we show an increase in
Tregs with response to treatment. We used CD25++, CD127- as Treg markers leaving the
possibility activated T-cells were counted. Lenalidomide has been shown to increase CD4+
Foxp3 cells in patients with multiple myeloma, suggesting a potential drug specific effect36.
Absolute numbers of circulating HLA-DR+ CD4+ T-cells, a rare circulating cell-type in our
study, increased in four subjects, including the nonresponder (Figure 4C). A correlation
between CLE clinical activity and HLA-DR expression on CD4+ and CD8+ T cells has been
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described. We believe this correlation requires further investigation in the setting of
treatment.
Finally, we saw unique changes in subject 5, the patient whose skin responded but
developed systemic symptoms of SLE at week 20 of the study (Figure 4D). This patient had
a robust increase in activated pDCs which may correlate with systemic symptoms, as SLE is
associated with high levels of serum IFNαwhich activated pDCs produce30. We cannot
exclude a predisposition to develop SLE. She was the only subject to report arthralgias at
baseline and was lymphopenic at weeks 2 and 6. Lymphopenia has been described as a
marker for SLE development in CLE patients37. In light of this event and evidence of cell
activation, we caution of the risk of systemic disease activation with lenalidomide.
In summary, lenalidomide reduced CLE activity in four of five subjects. The histology and
circulating leukocyte profile of five patients with severe treatment refractory CLE is
described, including CD8 predominant infiltrate in three subjects. The nonresponder had
high CXCL10 expression in the skin and increased activated circulating CD4+T-cells.
Responders with DLE had a decrease in GAG content. Clinical response was also associated
with a trend towards increased circulating Tregs and decreased circulating pDCs. In
addition, we noted a decrease in IFN-mediated gene expression in the peripheral blood and
IFN-inducible chemokine expression in the skin that did not correlate with clinical response.
Finally, we documented evidence of cellular activation and caution that lenalidomide may
activate T-cells and pDCs, triggering systemic disease in a subset of CLE patients.
The small subject pool limits recommendations on patient selection and monitoring
parameters. However patients with signs of systemic disease such as arthralgias may not be
candidates. In considering the use of this medication for treatment refractory CLE it would
be prudent to monitor for signs and symptoms of SLE, including a CBC with differential to
look for cytopenias. Additional study is required to understand the predictive value of more
specialized laboratory studies in predicting response to lenalidomide therapy. Further work
to identify SLE susceptibility risk factors in CLE patients may be informative in safely
selecting patients that would benefit from lenalidomide.
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Figure 1.
Representative images from a responding subject, subject 4, baseline (week 0) lesional skin.
(a) Hematoxylin & Eosin (H&E) stain, (b) CD3 (c) CLA (d) CD4 (e) CD8. Scale bar = 500
μm for H&E, panel (A), and Scale bar = 100 μm for remaining stains, panels (B)-(E).
Braunstein et al. Page 10
Figure 2.
Decrease in Hale’s staining in responding subjects with DLE. Hale’s staining highlights
glycosaminoglycan (GAG) content (blue). Images from subject 2, nonresponder, and subject
4, a responder with DLE, before and after treatment are shown. Subjects 1, 4 and 5 had
similar decrease in GAG staining at week 6. Week 0, lesional: (A) subject 2, (B) subject 4;
and Week 6, lesional: (C) subject 2, (D) subject 4. Scale bar = 500 μm.
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Figure 3.
CXCL10 expression in lesional skin decreases in basal keratinocytes and around
lymphocytes with lenalidomide treatment. Panels (a-h): Representative images of highest
staining for subjects 2 and 3 are shown for lesional skin at week 0, week 2, and week 6.
Subject 2: (A) week 0, (B) week 0 high power, (C) week 2, (D) week 6, Subject 3: (E) week
0, (F) week 0 high power, (G) week 2, and (H) week 6. Scale bar = 500 μm, except scale bar
= 100 μM for high power. Panel (I) Graphic representation of the change in percent
CXCL10 staining area with treatment.
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Figure 4.
Changes in the circulating leukocyte profile that correlate with clinical response. (A)
Percent-change in plasmacytoid dendritic cells (pDCs) (CD4- CD33-CD123+ CD11c-) from
baseline to week 6. Subjects who experienced skin improvement had an average 74%
decrease in pDC percentage (mean ± SEM: -74% ± 7%) vs. a 28% increase in the
nonresponder; (B) Absolute numbers of regulatory T-cell (Treg) (CD4+ CD25++ CD127-)
increased from week 0 to week 6 in responders. Subjects who experienced skin
improvement had a mean 4.1-fold increase in Treg percentage (mean ± SEM: 4.1-fold
increase ± 1.84-fold increase) vs. a 0.13-fold increase in the nonresponder; © Absolute
numbers of activated CD4+ T-cells increased (CD3+ CD4+ HLA-DR+ CD25+) from week
0 to week 6. (D) Increase in activated pDCs (CD4- CD33- CD123+ CD11c- CD40+ HLA-
DR+) in subject 5. Subject 5 had a robust and unique increase in activated pDCs.
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